No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Improved Revenues Required Before Ji Yao Holding Group Co., Ltd. (SZSE:300108) Stock's 37% Jump Looks Justified
*Ji Yao Holding Group (300108.SZ): Expected loss of 0.5 billion yuan to 0.85 billion yuan in 2024.
*ST Ji Yao Holding Group (300108.SZ) announced on January 21 that it expects a loss of 500 million to 850 million yuan in 2024, with a non-recurring loss of 440 million to 790 million yuan, and revenue of 320 million to 360 million yuan. The equity attributable to shareholders of the listed company is expected to be -830 million to -1,180 million yuan. 1. The main reason for the loss attributable to shareholders of the listed company for the year is that it has increased from the same period last year due to provisions for credit impairment losses, asset impairment losses, and others. 2. At the end of this year, attributable to the listed company.
*ST Jiyao: Ji Yao Holding Group Co., Ltd. 2024 Annual Results Forecast
Strong Week for Ji Yao Holding Group (SZSE:300108) Shareholders Doesn't Alleviate Pain of Five-year Loss
Ji Yao Holding Group Co., Ltd.'s (SZSE:300108) 32% Share Price Surge Not Quite Adding Up